Laboratory parameters were assessed using standard methods in our laboratory, including plasma NTproBNP (N-terminal pro-B-type natriuretic peptide) (immunoenzymatic; Siemens, Marburg, Germany) and troponin-I (immunoenzymatic single Dimension RxLMax; Siemens). Quantikine ELISA Immunoassay kit by R&D Systems (Minneapolis, MN) was used to determine the serum level of VEGF-C based on the frozen samples. This assay employs the quantitative sandwich enzyme immunoassay technique. The research was performed by the laboratory of the Department of Clinical Pharmacology at Wroclaw Medical University.
Nt probnp
Manufactured by Siemens
Sourced in Germany
NT-proBNP is a laboratory test used to measure the levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) in the blood. NT-proBNP is a protein produced by the heart in response to increased pressure or strain on the heart muscle. The test is commonly used to help diagnose and monitor certain heart conditions, such as heart failure.
Automatically generated - may contain errors
Lab products found in correlation
5 protocols using nt probnp
1
Cardiovascular Biomarkers Assessment
2
Comprehensive Clinical Laboratory Evaluation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The following laboratory parameters were assessed in all patients using standard methods: blood counts (haemoglobin and platelets); renal function (creatinine and blood urea nitrogen); electrolytes (sodium and potassium); and plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (immunoenzymatic assay, Siemens, Marburg, Germany).
3
Cardiac Biomarker Sampling Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Blood samples were collected immediately prior to cardiac catheterization and were drawn from the access site (either femoral or radial) used for the procedure. For each blood draw, 15 mL of blood was obtained into chilled tubes containing ethylenediaminetetraacetic acid (EDTA) or no anticoagulant and transported on ice to the lab for processing. Blood was subsequently centrifuged for 10 min at 3000 g, and plasma or serum was divided into 500 μL aliquots and stored at −80°C until analysis None of the aliquots used for this study were previously thawed. When assays were run, they were done all off of the same lot of reagent, batching samples into a single run. In this study, we evaluated hs‐cTnI (Abbott Diagnostics, Abbott Park IL), galectin‐3 (Abbott Diagnostics, Abbott Park IL), soluble urokinase plasminogen activator receptor (suPAR; ViroGates, Birkeroed, Denmark), NT‐proBNP (Siemens Inc, Newark DE), high‐sensitivity C‐reactive protein (hs‐CRP; Siemens, Newark, DE), cystatin‐C (Siemens, Newark, DE), myeloperoxidase (MPO; Siemens, Newark, DE), soluble ST2 (sST2; Critical Diagnostics, San Diego, CA), Kidney Injury Molecule‐1 (KIM‐1; Singulex Inc, Alameda CA), and endothelin‐1 (ET‐1; Singulex, Alameda, CA).
4
Comprehensive Biomarker Assessment Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
At the predefined time points, the following laboratory measurements were recorded using standard methods: -capillary blood for oxygen saturation, carbon dioxide concentration, pH, bicarbonate, and lactate (direct method, ABL 800 Flex analyser, Radiometer, Copenhagen, Denmark) (on admission and at 24 h); -haematology: haemoglobin, white blood cell count, and platelet count (on admission and at 48 h); -serum electrolytes: sodium (Na + ) and potassium (K + ) (on admission, at 24 h, and at 48 h); -renal function tests: creatinine and blood urea nitrogen (on admission, at 24 h, and at 48 h); -liver function tests: aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, and albumin (on admission); -plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP; immunoenzymatic assay, Siemens, Marburg, Germany) (on admission and at 48 h).
5
Comprehensive AHF Patient Assessment
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
After inclusion into the study, information on demographics, co‐morbidities, and clinical history was collected together with careful physical examination (for details, see succeeding text).
On admission at the emergency department (as a part of a standard AHF care), venous blood samples were obtained from all studied patients and subsequently after 24 and 48 h. The following laboratory measurements were assessed using standard methods in our laboratory: (i) haematology: haemoglobin (g/dL), haematocrit (%), and leukocytes (white blood cell, g/dL); (ii) electrolytes: sodium (mEq/L) and potassium (mEq/L); (iii) renal and liver function tests: serum creatinine (mg/dL), urea (mg/dL), estimated glomerular filtration rate (mL/min/1.73 m2), bilirubin (mg/dL), aspartate transaminase (IU/L), alanine transaminase (IU/L), gamma‐glutamyl transferase (IU/L), and albumin (mg/dL); (iv) plasma N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP, pg/mL) using an immunoenzymatic method (Siemens, Germany); (v) high‐sensitivity cardiac troponin I (ng/mL) using chemiluminescence (technology LOCI) on Dimension EXL System (Siemens Healthcare Diagnostics, Erlangen, Germany); (vi) C‐reactive protein (CRP, mg/L) using an immunoturbidimetric method (Konelab 30, Finland); and (vii) acid–base balance in the capillary blood sample.
Echocardiography was performed at the discretion of treating physician.
On admission at the emergency department (as a part of a standard AHF care), venous blood samples were obtained from all studied patients and subsequently after 24 and 48 h. The following laboratory measurements were assessed using standard methods in our laboratory: (i) haematology: haemoglobin (g/dL), haematocrit (%), and leukocytes (white blood cell, g/dL); (ii) electrolytes: sodium (mEq/L) and potassium (mEq/L); (iii) renal and liver function tests: serum creatinine (mg/dL), urea (mg/dL), estimated glomerular filtration rate (mL/min/1.73 m2), bilirubin (mg/dL), aspartate transaminase (IU/L), alanine transaminase (IU/L), gamma‐glutamyl transferase (IU/L), and albumin (mg/dL); (iv) plasma N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP, pg/mL) using an immunoenzymatic method (Siemens, Germany); (v) high‐sensitivity cardiac troponin I (ng/mL) using chemiluminescence (technology LOCI) on Dimension EXL System (Siemens Healthcare Diagnostics, Erlangen, Germany); (vi) C‐reactive protein (CRP, mg/L) using an immunoturbidimetric method (Konelab 30, Finland); and (vii) acid–base balance in the capillary blood sample.
Echocardiography was performed at the discretion of treating physician.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!